PDF(Pubmed)
Abstract：
UNASSIGNED: Due to their low cost, less invasive nature, and ready availability, plasma biomarkers of Alzheimer\'s disease have been proposed as one-time screening tools for clinical trials and research. The impact of ethnoracial factors on these biomarkers has received little attention. The current cross-sectional study investigated the levels of Aβ40, Aβ42, total tau (t tau), and neurofilament light (NfL) across diagnoses for each of the three major ethnoracial groups in the United States in a community-based cohort of older adults.
UNASSIGNED: A total of 1,862 participants (852 Mexican Americans (MAs); 775 non-Hispanic Whites (NHWs), and 235 African Americans (AAs)) drawn from The Health & Aging Brain Study-Health Disparities (HABS-HD) study were included. Diagnoses were assigned using an algorithm (decision tree) verified by consensus review. Plasma samples were assayed using Simoa technology. Levels of each biomarker were compared for the three ethnoracial groups across cognitive diagnoses using ANOVA covarying sex and age.
UNASSIGNED: Significant differences were found across the groups at each level of cognitive impairment. Cognitively unimpaired (CU) AA had significantly lower levels of each of the biomarkers than cognitively unimpaired MA or NHW and NHW had higher levels of Aβ40, and NfL than the other two groups. MA had higher t tau than AA or NHW. Mild cognitive impairment (MCI) group NHW had the highest levels on all the biomarkers and AA had the lowest. NHW and MA have higher levels of Aβ40, Aβ42, and t tau there was no difference between the groups for Aβ42. NHW had significantly higher levels of Aβ40, t tau, and NfL than AA. AA had a higher Aβ42/Aβ40 ratio than either NHW or MA for CU MCI.
UNASSIGNED: The use of plasma biomarkers of cognitive decline is promising given their advantages over other biomarkers such as CSF and imaging but as the current research shows, ethnoracial differences must be considered to enhance accuracy and utility. Developing ethnoracial-specific cut points and establishing normative ranges by assay platform for each of the biomarkers are needed. Longitudinal research to assess changes in biomarkers during a cognitive decline is ongoing.
UNASSIGNED: A total of 1,862 participants (852 Mexican Americans (MAs); 775 non-Hispanic Whites (NHWs), and 235 African Americans (AAs)) drawn from The Health & Aging Brain Study-Health Disparities (HABS-HD) study were included. Diagnoses were assigned using an algorithm (decision tree) verified by consensus review. Plasma samples were assayed using Simoa technology. Levels of each biomarker were compared for the three ethnoracial groups across cognitive diagnoses using ANOVA covarying sex and age.
UNASSIGNED: Significant differences were found across the groups at each level of cognitive impairment. Cognitively unimpaired (CU) AA had significantly lower levels of each of the biomarkers than cognitively unimpaired MA or NHW and NHW had higher levels of Aβ40, and NfL than the other two groups. MA had higher t tau than AA or NHW. Mild cognitive impairment (MCI) group NHW had the highest levels on all the biomarkers and AA had the lowest. NHW and MA have higher levels of Aβ40, Aβ42, and t tau there was no difference between the groups for Aβ42. NHW had significantly higher levels of Aβ40, t tau, and NfL than AA. AA had a higher Aβ42/Aβ40 ratio than either NHW or MA for CU MCI.
UNASSIGNED: The use of plasma biomarkers of cognitive decline is promising given their advantages over other biomarkers such as CSF and imaging but as the current research shows, ethnoracial differences must be considered to enhance accuracy and utility. Developing ethnoracial-specific cut points and establishing normative ranges by assay platform for each of the biomarkers are needed. Longitudinal research to assess changes in biomarkers during a cognitive decline is ongoing.
摘要：
未经ASSIGNED：由于其低成本，侵入性较小，和现成的可用性，阿尔茨海默病的血浆生物标志物已被提议作为临床试验和研究的一次性筛选工具。一氧化氮因子对这些生物标志物的影响很少受到关注。当前的横断面研究调查了Aβ40，Aβ42，总tau（ttau）的水平，和神经丝光（NfL）在基于社区的老年人队列中，对美国三个主要的小鼠组进行诊断。
未经评估：共有1,862名参与者（852名墨西哥裔美国人（MA）；775名非西班牙裔白人（NHW），和235非洲裔美国人（AA））来自健康与衰老大脑研究-健康差异（HABS-HD）研究。使用经共识审查验证的算法(决策树)分配诊断。使用Simoa技术测定血浆样品。使用ANOVA协方差性别和年龄，比较了三个认知诊断中每个生物标志物的水平。
UNASSIGNED：在认知损害的每个水平上，各组之间都发现了显著差异。与认知未受损的MA或NHW相比，认知未受损（CU）AA的每种生物标志物的水平均显着较低，而NHW的Aβ40和NfL水平高于其他两组。MA的ttau高于AA或NHW。轻度认知障碍（MCI）组NHW在所有生物标志物中的水平最高，AA最低。NHW和MA的Aβ40，Aβ42和ttau水平较高，两组之间的Aβ42没有差异。NHW有明显较高水平的Aβ40，ttau，NfL比AA。对于CUMCI，AA的Aβ42/Aβ40比率高于NHW或MA。
UNASSIGNED：使用认知功能减退的血浆生物标志物是有希望的，因为它们优于其他生物标志物，如CSF和成像，但正如目前的研究表明，为了提高准确性和实用性，必须考虑药物的差异。需要通过测定平台为每种生物标志物开发特定于乙醇的切点并建立规范范围。评估认知衰退期间生物标志物变化的纵向研究正在进行中。
未经评估：共有1,862名参与者（852名墨西哥裔美国人（MA）；775名非西班牙裔白人（NHW），和235非洲裔美国人（AA））来自健康与衰老大脑研究-健康差异（HABS-HD）研究。使用经共识审查验证的算法(决策树)分配诊断。使用Simoa技术测定血浆样品。使用ANOVA协方差性别和年龄，比较了三个认知诊断中每个生物标志物的水平。
UNASSIGNED：在认知损害的每个水平上，各组之间都发现了显著差异。与认知未受损的MA或NHW相比，认知未受损（CU）AA的每种生物标志物的水平均显着较低，而NHW的Aβ40和NfL水平高于其他两组。MA的ttau高于AA或NHW。轻度认知障碍（MCI）组NHW在所有生物标志物中的水平最高，AA最低。NHW和MA的Aβ40，Aβ42和ttau水平较高，两组之间的Aβ42没有差异。NHW有明显较高水平的Aβ40，ttau，NfL比AA。对于CUMCI，AA的Aβ42/Aβ40比率高于NHW或MA。
UNASSIGNED：使用认知功能减退的血浆生物标志物是有希望的，因为它们优于其他生物标志物，如CSF和成像，但正如目前的研究表明，为了提高准确性和实用性，必须考虑药物的差异。需要通过测定平台为每种生物标志物开发特定于乙醇的切点并建立规范范围。评估认知衰退期间生物标志物变化的纵向研究正在进行中。
